Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

BJU international·2026
Same author

FLInt 2.0: Robust and customizable single shot integration in C. elegans.

G3 (Bethesda, Md.)·2026
Same author

FLInt 2.0: Robust and customizable single shot integration in <i>C. elegans</i>.

bioRxiv : the preprint server for biology·2026
Same author

Sticker shock: evaluation of a novel internal medicine clerkship high-value care curriculum using patient bills.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Exploring the link between unmet needs and quality of life in lymphoma survivors: a cross-sectional study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Effect of practice on the control of reach extent.

Experimental brain research·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Bacillus Calmette-Guérin Therapy: Optimizing Outcomes amid Challenges.

Tutku E Tazegul1, Michael O'Donnell1, Helen Y Hougen1

  • 1Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA 52242, USA.

The Urologic Clinics of North America
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

Bacillus Calmette-Guérin (BCG) immunotherapy is crucial for bladder cancer but faces challenges. This review explores BCG alternatives, optimization strategies, and emerging treatments for improved patient outcomes.

Keywords:
BCG shortageBCG-Unresponsive diseaseBacillus Calmette-Guérin

More Related Videos

Galleria mellonella as an Antimicrobial Screening Model
06:19

Galleria mellonella as an Antimicrobial Screening Model

Published on: October 11, 2024

Related Experiment Videos

Last Updated: Jun 28, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Galleria mellonella as an Antimicrobial Screening Model
06:19

Galleria mellonella as an Antimicrobial Screening Model

Published on: October 11, 2024

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Bacillus Calmette-Guérin (BCG) is the standard adjuvant immunotherapy for non-muscle invasive bladder cancer (NMIBC).
  • Clinical use of BCG is limited by supply shortages, intolerance, and inconsistent efficacy.
  • There is a growing need for alternative and optimized treatment strategies for NMIBC.

Purpose of the Study:

  • To review the immunologic principles, effectiveness, and limitations of BCG therapy.
  • To examine alternative administration methods and combination therapies for NMIBC.
  • To outline emerging treatments for BCG-unresponsive bladder cancer and provide management recommendations.

Main Methods:

  • Literature review of immunologic basis, clinical efficacy, and limitations of BCG.
  • Evaluation of alternative BCG administration strategies.
  • Assessment of combination therapies, biomarker-based patient selection, and novel agents for BCG-unresponsive disease.

Main Results:

  • BCG's efficacy is well-established but variable, with significant challenges in supply and tolerability.
  • Alternative administration schedules and combination approaches show promise in enhancing BCG effectiveness.
  • Emerging therapies offer new options for patients with BCG-refractory or BCG-unresponsive NMIBC.

Conclusions:

  • Optimizing BCG use through modified administration and patient selection is critical.
  • Biomarker-driven approaches are essential for personalizing NMIBC treatment.
  • Novel therapeutic strategies are expanding options for managing advanced or refractory NMIBC.